Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV’s optimism on the project. See below.

Andrew Satz is the CEO and Brett Averso is the CTO of a startup, EVQLV. This startup is making algorithms that can computationally generate, screen, and optimize countless therapeutic antibodies. Making use of their technology, EVQLV is trying to come up with treatments that are very likely to assist in the treatment of COVID-19 infected patients. The machine learning algorithm quickly screens for therapeutic antibodies that have higher chances of attaining success in the treatment of COVID-19 patients.

Satz states that it is possible to come up with a treatment for coronavirus ready by 2020-end, thanks to the international urgency to come up with a treatment for the same.

Read the entire piece here.